Transforming growth factor,81 (TGF-,B1) is a key regulator of cell growth and differentiation. Under normal physiological conditions, it is made as a biologically latent complex whose significance is unknown. Previous work has indicated that active TGF-,B1 has a very short plasma half-life in rats (Coffey, R. J., L. J. Kost, R. M. Lyons, H. L. Moses, and N. F. LaRusso. 1987. J. Clin. Invest. 80:750-757). We have investigated the possibility that latent complex formation may extend the plasma half-life of TGF-,@1 and alter its organ distribution. Radiolabeled latent TGF-fil was formed by noncovalent association of '25I-TGF-ftl with the TGF-,81 precursor "pro"' region from recombinant sources. TGF-h1 in this latent complex had a greatly extended plasma half-life (> 100 min) in rats compared with active TGF-,81 (2-3 min). Whereas active TGF-,B1 was rapidly taken up by the liver, kidneys, lungs, and spleen and degraded, TGF-,81 in the latent complex was largely confined to the circulation, and was < 5% degraded after 90 min. The pharmacokinetics of TGF-,81 in the latent complex were shown to be critically dependent on the degree of sialylation of the complex. The results suggest that formation of latent complexes may switch endogenous TGF-f1 from an autocrine/paracrine mode of action to a more endocrine mode involving target organs distant from the site of synthesis. (J.
Introduction
Transforming growth factor-#31 (TGF-,B1)' is the prototype ofa family of proteins that is intimately involved in the regulation of virtually every physiological process (for review see reference 1) . Experiments in animal model systems have indicated that TGF-,fl1 has great clinical potential in the areas of wound healing (2) , immunosuppression and myeloprotection (3), and TGF-# I differs from the majority of growth regulatory factors in that it is generally synthesized and secreted in a biologically latent form, and this must be activated before TGF-,B1 can exert its biological effects on target cells (5, 6) . The nature of the activation mechanism in vivo is unclear, but may involve proteases, and in some instances may be dependent on cell-cell interactions (7) (8) (9) . The major latent form of TGF-,13 that occurs naturally is a high molecular weight complex, in which the homodimeric active TGF-# I is noncovalently associated with a dimer of the remainder of its precursor "pro" region, and this in turn is disulfide-bonded to a third, structurally unrelated protein of 135 kD (10, 11) .
Recombinant systems expressing the entire coding region of the TGF-f31 gene also make TGF-,B1 in a latent form (12, 13) . However, in this case the latent complex consists only of active TGF-,3I, noncovalently associated with the precursor "pro" region. This indicates that the precursor "pro" sequence alone is sufficient to confer latency on TGF-B3l, and the 135-kD protein of the natural latent complex must have a different function. The dimeric form of the TGF-#1 precursor "pro" region is now termed the TGF-,B1 latency-associated peptide (LAP).
The in vivo significance of the latent form of TGF-pl is unclear. However, since it appears to be the predominant naturally occurring form of the molecule, it may be a more appropriate form of TGF-# 1 to use in many clinical settings than the active molecule. Given the pleiotropic effects of active TGF-t 1 on virtually every organ system, systemic administration of active TGF-3 1 may bypass normal regulatory mechanisms that operate on latent TGF-#31 to restrict its activity spatially and temporally, and could result in undesirable responses in non-target organs. Furthermore, recent data have indicated that active TGF-j31 has an extremely short plasma half-life in rats (14) . In the present work we have asked whether one role of latent complex formation might be to extend the plasma half-life of TGF-f31, and to alter its organ distribution. To do this, we have compared in rats the relative pharmacokinetics of active TGF-, 1, and latent TGF-# I complexes, formed by recombining '25I-TGF-,31 with TGF-,31 LAP from recombinant sources.
Methods
Assays for TGF-f31 and LAP Radioreceptor assays. Porcine platelet TGF-,B1 was obtained from R&D Systems Inc. (Minneapolis, MN), and iodinated to a specific activity of -80 ACi/4g by the modified chloramine T method (15) . The latent TGF-#I1 complex was quantitated by radioreceptor assay (13 (18) . Cells expressing DHFR were selected as described (18) . DHFR+ cells were screened for TGF-,13 expression by metabolic labeling and RIA (13 For purification of TGF-,BI LAP from the C3/12A clone, the conditioned medium was dialyzed and loaded on a Mono Q anion-exchange column as above. Since the latent complex produced by this culture system was anionic, due to more extensive sialylation of the complex than occurred with the MJB I clone (see Results), it bound to the column and was eluted at 0.05-0.1 M NaCl. Pooled peak fractions were dialyzed against 20 mM Tris-Cl, pH 7.5, containing 6 M urea, and fractionated on a Mono Q HR5/5 column, using a 0-0.3 M NaCl gradient in the presence of 6 M urea. The LAP eluted at 0.1 1-0.14 M NaCl, well separated from free TGF-,BI that eluted in the flow through, and from the bulk of contaminating protein that eluted at lower ionic strength. Pooled peak fractions were further purified on Superose 12 as above. SDS-PAGE analysis indicated the LAP was 40-50% pure. Because of the more extensive sialylation of this species, this material is referred to as S-LAP.
Neuraminidase digestion
The sialic acid content of the LAP samples was examined by comparing the molecular weight ofthe reduced LAP species on Western blots, before and after digestion of conditioned media or partially purified LAP protein overnight at 37°C with 14 U/ml soluble or immobilized neuraminidase (Type XA; Sigma Chemical Co., St. Louis, MO) in 100 mM sodium acetate, pH 5.6, containing 1 ,tg/ml leupeptin and pepstatin, and 2 ,g/ml aprotinin. Immunoblots of the conditioned media samples were probed with a polyclonal antibody against a synthetic peptide corresponding to residues 46-56 of the TGF-,BI precursor to visualize the LAP, as described ( 13) .
Pharmacokinetic studies
Labeled latent complex for the pharmacokinetic studies was made by incubating '251I-TGF-1l with an excess of LAP (2 40 U LAP/ng TGF-,1B), in PBS, overnight at 4°C. Each animal received the equivalent of 20-160 ng '251-TGF-f 1, corresponding to 1-8 ACi, in a volume of 0.5 ml. No difference in tissue distribution or plasma half-life was observed over this dose range. All experiments were conducted with male Sprague-Dawley rats weighing between 225 and 295 g. Rats were anesthetized with intraperitoneal pentobarbital (50 mg/kg). A PEIO catheter was introduced into the right iliac artery, and animals were heparinized by injection of -45 U of heparin in 0.1 ml PBS. Samples were injected into the contralateral femoral vein in a total volume of 0.5 ml. Blood samples of 0.15-0.2 ml were withdrawn from the iliac artery at timed intervals after sample injection. 10 U heparin was immediately added and plasma was prepared by spinning out the blood cells for 2 min in a microfuge. Both plasma and blood cell fractions were counted for radioactivity. Essentially no radioactivity was recovered in the blood cell fraction (data not shown). The extent of degradation of the labeled material in the plasma was assessed by determining the fraction of label that was precipitable by 20% TCA. Plasma half-lives for the various labeled species were determined from the rate of decay of TCA precipitable counts in the plasma with time. The distribution volumes were determined by extrapolation ofplasma radioactivity to t = 0 min, using the initial linear portion of the decay curve on a log plot. At the end of the time course, the animals were killed by pentobarbital overdose and organs were excised, weighed;
and counted for 1251I in a gamma counter. In some experiments the organs were then fixed in neutral buffered formalin for autoradiography. In others, the radioactive material in the organs was recovered by acid-ethanol extraction. Briefly, organs were minced, and 4 ml/g tissue of an ice-cold solution consisting of 93% EtOH, 230 mM HCI, 1 4g/ml PMSF, and 5 ,g/ml pepstatin was added. The tissue was immediately homogenized in a tissuemizer. Homogenates were then rocked overPharmacokinetics ofLatent Transforming Growth Factor f31 in Rat 1977 night at 4°C and centrifuged for 30 min at 3,000 g to remove insoluble material. The extent of degradation of the labeled material in each organ was then assessed by determining the fraction of extracted '25I that was precipitable by 20% TCA.
Since heparin has been shown to affect the association of active TGF-f3 and a-2-macroglobulin in vitro (16) , one experiment was performed in which the clearance of active TGF-3 was monitored in an unheparinized animal. Although blood clotting in the catheter prevented the construction ofa complete plasma clearance curve, the time points that were obtained were essentially superimposable on those obtained from heparinized animals, and the distribution of label between organs at the end ofthe experiment was identical in heparinized and nonheparinized animals (data not shown). All animals thereafter were heparinized.
Results
Formation of iodinated latent TGF-f3J complexes. lodinated latent TGF-,B1 complexes were formed by recombining partially purified recombinant LAP species with 125I-TGF-31 of high purity. This approach was chosen since TGF-#31 is relatively inaccessible in the latent complex and iodination of intact latent complex would be expected to label the LAP rather than the TGF-# 1 (13) . All recombinant LAP species caused a dose-dependent inhibition of the ability of '25I-TGF-l1 to bind to its receptor on A549 cells, indicating that latent complexes had formed (Fig. 1) . Treatments that are known to (Fig. 2 A, lanes I and 2) . However, when combined with U-LAP, the form of LAP made by the MJ,Bl clone, a new species formed that migrated towards the cathode (Fig. 2 A, lane 3) . Heating the sample to 80°C for 5 min resulted in the disappearance ofthis species (Fig. 2 A, lane  4) . Similar results were obtained with S-LAP, the form of LAP that was made by the C3/ 1 2A clone. However, in this case the complex had a net negative charge and migrated in the opposite direction (Fig. 2 A, lanes 5 and 6) . Taken together, the data indicate that the partially purified LAP species are capable of recombining with iodinated TGF-flI to form biologically latent complexes.
Pharmacokinetics of latent TGF-plJ in rat. The latent TGF-,l complexes were injected into rats to determine the plasma half-lives, and the results are presented in Table I . Active TGF-gl was cleared very rapidly from rat plasma with a half-life of 2-3 min, in agreement with previously published work (14) . Initial experiments in which latent TGF-fll was in a greater than sevenfold increase in the half-life of the latent complex, consistent with its clearance via this route (Table I) . Western blot comparison of the LAP protein in conditioned media from the MJJ31 and C3/12A clones, before and after treatment with neuraminidase, indicated that the LAP made by the MJ.Il clone (U-LAP) was undersialylated compared with that from the C3/12A clone (S-LAP) (Fig. 2 B) . The molecular weight of the reduced S-LAP (36-39 kD) was similar to that observed for LAP derived from human platelet latent TGF-# (10) . Latent complex formed with S-LAP had a greatly extended plasma half-life of > 100 min (Table I) . Removal of sialic acid from S-LAP by neuraminidase digestion resulted in formation of a latent complex with the same very short half-life as complexes formed with U-LAP. Representative plasma decay curves for '251I-TGF-f3I with and without S-LAP are shown in Fig. 3 . Figure 3 . Effect of latent complex formation on the disappearance of circulating '25I-TGF-f. 1 from rat plasma. '251-TGF-#3I, alone or complexed with S-LAP, was injected into the femoral artery and the TCA precipitable counts in the plasma were determined at various times after injection, as described in Methods. Data points are the TCA precipitable cpm in 100 A1 plasma, normalized to 5 X 106 cpm injected. In this experiment, the plasma half-life for the active TGF-B was 3.1 min, and that for the latent TGF-,B was 1 10.0 min. Data collection for the latent complex was continued up to t = 90 min to allow more accurate determination of the half-life. Active TGF-,B (-), latent TGF-,B (TGF-,B + S-LAP) (o). the extracellular fluid or some organ sink. In contrast, the Vd for latent TGF-# I formed with S-LAP was -17 ml, suggesting that the latent complex is largely confined to the circulatory system (Table I ). This was confirmed by analysis of the recovery of radioactivity in the various organs upon killing the animal. For active TGF-# 1, more radioactivity was recovered in the liver than in any other organ, and only -4% was recovered in the plasma at 20 min after injection (Fig. 4 A) . By contrast, for latent TGF-, 1 formed with S-LAP, only 8% ofthe radioactivity was recovered in the liver as late as 90 min after injection, and all other organs had . 2%, whereas 62.9±6.1% was recovered in the plasma. The recovery ofactive TGF-, I in the liver is consistent with previously published data suggesting that active TGF-# 1 is cleared by this organ (14) . Interest- ingly, while the liver had the largest amount of TGF-#, normalization of recovered radioactivity to organ wet weight indicated that 125I-TGF-fBl was actually most concentrated in the lungs. The concentration in kidneys, spleen, and liver were comparable to each other and approximately half that in the lungs (Fig. 4 B) . By contrast, very little of the '25I-TGF-#3I in the latent complex formed with S-LAP was found in any organ, as long as 90 min after injection, confirming that the majority of this complex does not pass out of the circulation (Fig. 4 B) . As expected, the latent complex formed with U-LAP or with desialylated S-LAP was recovered almost exclusively in the liver. (14) . In the kidney, labeled material was concentrated in the glomeruli, and in the lung it was found throughout the interstitium. The 1251I in the spleen localized to an area surrounding the white pulp, but was largely excluded from the red pulp and the center of the white pulp. By contrast, in animals that had been injected with the fully sialylated latent TGF-, 1, the majority of the iodinated material was associated with the blood, and there was little labeling above background in any organ. The only significant concentration of label was observed in the wall of a large blood vessel in the lung (Fig. 6 B) . Since no sections from the other organs contained large blood vessels, it is not clear if this is a feature specific to the lung. However, it is apparent that in addition to distributing at low levels to most organs (see Fig. 4 ), the latent complex may concentrate in certain sites outside the circulatory system.
Degradation ofcirculating TGF-13J. By 15 min after injection of active 251I-TGF-# 1, only 53±17% of the radioactivity recovered from the plasma was precipitatable by TCA (Fig. 7) . This indicates that active TGF-j 1 is rapidly degraded and that some of the degradation products either remain in or reenter the circulation. By contrast, the '25I-TGF-f1 in the latent complex formed with S-LAP appeared to be protected from this degradation process, with < 5% of the circulating material degraded, as long as 90 min after injection.
Analysis by SDS-PAGE of the iodinated material circulating in the plasma 30 min after injection of the animals with latent TGF-,B (251I-TGF-# + S-LAP), confirmed that there is little degradation of the '25I-TGF-,3 in the complex, as indicated by the absence of bands below the band corresponding to intact TGF-,B at 25 kD (Fig. 8, lane 3) . Chemical cross-linking of the labeled material in the plasma before electrophoresis gives a band at 100 kD (Fig. 8, lanes 2 and 4) , characteristic of the recombinant latent complex (Fig. 8, lane 8) . This suggests that the latent complex is circulating in the form in which it was injected. Note that chemical cross-linking reactions of this type are low efficiency, so only a fraction of the complex is crosslinked and stable to the denaturing conditions of electrophoresis. In the case of animals injected with active TGF-,B (125I-TGF-,3 alone), the very rapid clearance results in a low ratio of radioactivity to total plasma protein which precludes analysis of these samples by SDS-PAGE.
Extent of degradation of '25I-TGF-f3 in tissues. To determine whether the radioactivity seen in the tissue autoradio- (14) . We have additionally shown a significant uptake of active TGF-#3 by lungs, spleen, and kidneys. The overall distribution patter is similar to that observed for clearance of a-2-macroglobulin (a2M) (22, 23) and is consistent with the proposal that active TGF-pls may complex with a2M and be cleared in this form (24 TGF-#l is secreted in an active form (25, 26) . In this way cells may be able to exert some control over the range of action of the TGF-f3l that they secrete. Normal human plasma contains significant levels of TGF-3 from non-platelet sources (1.5±0.6 ng/ml (n = 10); Wakefield, L. M., unpublished data). The plasma TGF-j is latent, and while the lack ofsensitive reagents for detecting latent TGF-# complexes so far precludes identification of the type of latent complex, it is clear that latent TGF-# does circulate in normal individuals and may play an important role in mediating regulatory interactions between organs.
In a clinical setting, the longer half-life of the latent TGF-l1 complex could be advantageous in greatly extending the duration of action of a single injected dose of the factor. Furthermore, the demonstration that systemically administered active TGF-ll becomes concentrated in the lungs, kidneys, and spleen, as well as the liver, is potentially problematic in relation to the known ability of TGF-#3I to cause fibrosis in vivo (27) . It will be important to determine whether the TGF-, I delivered to these sites can exert any biological effect. In contrast, correctly sialylated latent TGF-,B1 did not accumulate appreciably in any one organ, but seemed to distribute at low levels among them all, with the only significant concentration of latent TGF-,B1 in any organ being to the wall of a large blood vessel in the lung.
It is not yet known which cell types are capable of activating latent TGF-,B1 in vivo, but clearly this will determine the clinical targets for the latent complex, since it appears to distribute at low levels to most perfused organs. When large quantities of purified recombinant latent TGF-# 1 become available, it should be possible to infuse animals with the material and look for effects on different organ systems. We have shown that the degree of sialylation of the latent complex is critical in determining both half-life and organ distribution. Since recombinant expression systems are variable in the degree to which they sialylate proteins (19) , and all clinical work is likely to be done with recombinant material, it will be vital for investigators using this material to confirm that it has an adequate degree of sialylation. Furthermore, while native platelet and recombinant latent TGF-31 are very similar in many in vitro properties (13, 20) , it will be important to compare these in vivo. This may provide clues as to the role of the additional 135-kD protein in the natural latent TGF-,B1, and will allow assessment of the degree to which the recombinant form will mimic or improve upon the natural complex in a clinical setting.
